Article Details

Kindred Biosciences Initiates Pivotal Efficacy Study of Tirnovetmab (Interleukin-31) Monoclonal ...

Retrieved on: 2020-12-22 13:30:00

Tags for this article:

Click the tags to see associated articles and topics

Kindred Biosciences Initiates Pivotal Efficacy Study of Tirnovetmab (Interleukin-31) Monoclonal .... View article details on hiswai:

Excerpt

Other programs in development for atopic dermatitis include KIND-032, a fully caninized monoclonal antibody targeting IL-4R. A second pilot study to ...

Article found on: www.prnewswire.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up